Market reaction and overview
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) experienced a 9.6% decline in premarket trading Tuesday after it released updated efficacy and safety data from the ongoing Phase 1/2 study of CRB-701, its Nectin-4-directed antibody-drug conjugate.
Efficacy results from the April 1, 2026 data cut
The company reported results derived from a data cut on April 1, 2026. At the 3.6 mg/kg dose level, CRB-701 produced a confirmed objective response rate (ORR) of 42.9% in second-line oropharyngeal squamous cell carcinoma, with a median duration of response of 6.3 months and a median progression-free survival (PFS) of 5.6 months. In second-line cervical cancer at the same dose, the confirmed ORR was 34.4%, with a median duration of response of 8.0 months and median PFS of 4.3 months.
Study population and data scope
The Phase 1/2 program's safety population comprised 317 patients overall. Within that population, 75 patients with head and neck squamous cell carcinoma were enrolled across the 2.7 mg/kg and 3.6 mg/kg dose cohorts, and 72 patients with cervical cancer were enrolled across those same doses.
Safety profile
CRB-701's reported safety profile included treatment discontinuations attributed to the drug at 2.8%. The most frequently observed treatment-related adverse events listed were keratitis at 49.2%, alopecia at 25.6%, fatigue at 22.4%, and dysgeusia at 19.9%. Grade 3 adverse events occurred in 19.2% of patients, and Grade 4 adverse events were reported in 0.9% of patients.
Regulatory path and next steps
Corbus said it remains on schedule to start a registrational study of CRB-701 in second-line oropharyngeal squamous cell carcinoma in summer 2026. The company reported it had reached broad alignment with the U.S. Food and Drug Administration on the design of a randomized controlled trial expected to enroll 250 patients.
Implications for markets and sectors
The updated dataset coincided with immediate market movement in Corbus shares. The information will be of interest to investors focused on biotechnology and healthcare equities, as well as market participants tracking oncology pipelines and clinical development milestones.
What remains in focus
Key upcoming items include the planned initiation of the registrational trial in summer 2026 and execution of the randomized 250-patient study aligned with the FDA. The companys published safety and efficacy figures from the April 1, 2026 data cut will form the basis for that next-stage study.
Data reported in this article are those provided by the company in its updated Phase 1/2 release and are presented without additional interpretation beyond the information disclosed.